FDA asks where to add patient perspectives

FDA is looking to expand its patient-driven drug development process by inviting stakeholders to weigh in on "strategies to solicit the views of patients during the medical product development process and consider the perspectives of patients during regulatory discussions."

According to its Federal Register notice, FDA is interested in comments "on both current and new activities that would involve patient participation in regulatory discussions, as well as comments on ways to assess patient participation activities." ...